<?xml version="1.0" encoding="utf-8" standalone="no"?>
<dublin_core schema="dc">
<dcvalue element="contributor" qualifier="author">Ali,&#x20;Eslam&#x20;M.&#x20;H.</dcvalue>
<dcvalue element="contributor" qualifier="author">Abdel-Maksoud,&#x20;Mohammed&#x20;S.</dcvalue>
<dcvalue element="contributor" qualifier="author">Ammar,&#x20;Usama&#x20;M.</dcvalue>
<dcvalue element="contributor" qualifier="author">Mersal,&#x20;Karim,&#x20;I</dcvalue>
<dcvalue element="contributor" qualifier="author">Yoo,&#x20;Kyung&#x20;Ho</dcvalue>
<dcvalue element="contributor" qualifier="author">Jooryeong,&#x20;Park</dcvalue>
<dcvalue element="contributor" qualifier="author">Oh,&#x20;Chang-Hyun</dcvalue>
<dcvalue element="date" qualifier="accessioned">2024-01-19T15:33:54Z</dcvalue>
<dcvalue element="date" qualifier="available">2024-01-19T15:33:54Z</dcvalue>
<dcvalue element="date" qualifier="created">2022-01-10</dcvalue>
<dcvalue element="date" qualifier="issued">2021-01</dcvalue>
<dcvalue element="identifier" qualifier="issn">0045-2068</dcvalue>
<dcvalue element="identifier" qualifier="uri">https:&#x2F;&#x2F;pubs.kist.re.kr&#x2F;handle&#x2F;201004&#x2F;117573</dcvalue>
<dcvalue element="description" qualifier="abstract">BRAF(V600E)&#x20;mutation&#x20;has&#x20;been&#x20;detected&#x20;in&#x20;various&#x20;malignant&#x20;tumours.&#x20;Developing&#x20;of&#x20;potent&#x20;BRAF(V600E)&#x20;inhibitors&#x20;is&#x20;considered&#x20;a&#x20;leading&#x20;step&#x20;in&#x20;the&#x20;way&#x20;to&#x20;cure&#x20;different&#x20;cancer&#x20;types.&#x20;In&#x20;the&#x20;current&#x20;work,&#x20;a&#x20;series&#x20;of&#x20;38&#x20;4-(1Himidazol-5-yl)pyridin-2-amine&#x20;derivatives&#x20;was&#x20;designed&#x20;and&#x20;synthesized&#x20;using&#x20;Dabrafenib&#x20;as&#x20;a&#x20;lead&#x20;compound&#x20;for&#x20;structural-guided&#x20;optimization.&#x20;The&#x20;target&#x20;compounds&#x20;were&#x20;evaluated&#x20;as&#x20;potential&#x20;anticancer&#x20;agents&#x20;against&#x20;NCI&#x20;60&#x20;human&#x20;cancer&#x20;cell&#x20;lines.&#x20;In&#x20;5-dose&#x20;testing&#x20;mode,&#x20;two&#x20;compounds&#x20;14h&#x20;and&#x20;16e&#x20;were&#x20;tested&#x20;to&#x20;determine&#x20;their&#x20;IC50&#x20;values&#x20;over&#x20;each&#x20;of&#x20;the&#x20;60&#x20;cell&#x20;lines.&#x20;The&#x20;selected&#x20;candidates&#x20;exhibited&#x20;promising&#x20;activity&#x20;with&#x20;mean&#x20;IC(50&#x20;)values&#x20;of&#x20;2.4&#x20;mu&#x20;M&#x20;and&#x20;3.6&#x20;mu&#x20;M,&#x20;respectively.&#x20;Melanoma&#x20;cancer&#x20;cell&#x20;lines&#x20;exhibited&#x20;the&#x20;highest&#x20;sensitivity&#x20;after&#x20;the&#x20;treatment&#x20;with&#x20;the&#x20;tested&#x20;compounds&#x20;14h&#x20;and&#x20;16e.&#x20;The&#x20;mean&#x20;IC50&#x20;values&#x20;of&#x20;compounds&#x20;14h&#x20;and&#x20;16e&#x20;against&#x20;Melanoma&#x20;cancer&#x20;cell&#x20;lines&#x20;are&#x20;1.8&#x20;mu&#x20;M&#x20;and&#x20;1.88&#x20;mu&#x20;M,&#x20;respectively.&#x20;In&#x20;addition,&#x20;BRAF&#x20;v600E&#x20;kinase&#x20;inhibitory&#x20;activity&#x20;was&#x20;determined&#x20;for&#x20;each&#x20;derivative.&#x20;Compounds&#x20;15i,&#x20;15j,&#x20;16a,&#x20;and&#x20;16d&#x20;were&#x20;the&#x20;most&#x20;potent&#x20;inhibitors&#x20;against&#x20;BRAF(V600E)with&#x20;IC50&#x20;76&#x20;nM,&#x20;32&#x20;nM,&#x20;35&#x20;nM,&#x20;and&#x20;68&#x20;nM.&#x20;The&#x20;newly&#x20;developed&#x20;compounds&#x20;represent&#x20;a&#x20;therapeutically&#x20;promising&#x20;approach&#x20;for&#x20;the&#x20;treating&#x20;various&#x20;cancer&#x20;types.</dcvalue>
<dcvalue element="language" qualifier="none">English</dcvalue>
<dcvalue element="publisher" qualifier="none">ACADEMIC&#x20;PRESS&#x20;INC&#x20;ELSEVIER&#x20;SCIENCE</dcvalue>
<dcvalue element="subject" qualifier="none">ANTIPROLIFERATIVE&#x20;ACTIVITY</dcvalue>
<dcvalue element="subject" qualifier="none">B-RAF(V600E)&#x20;INHIBITORS</dcvalue>
<dcvalue element="subject" qualifier="none">MULTIKINASE&#x20;INHIBITOR</dcvalue>
<dcvalue element="subject" qualifier="none">C-RAF</dcvalue>
<dcvalue element="subject" qualifier="none">B-RAF</dcvalue>
<dcvalue element="subject" qualifier="none">BRAF</dcvalue>
<dcvalue element="subject" qualifier="none">KINASE</dcvalue>
<dcvalue element="subject" qualifier="none">MELANOMA</dcvalue>
<dcvalue element="subject" qualifier="none">CANCER</dcvalue>
<dcvalue element="subject" qualifier="none">DABRAFENIB</dcvalue>
<dcvalue element="title" qualifier="none">Design,&#x20;synthesis,&#x20;and&#x20;biological&#x20;evaluation&#x20;of&#x20;novel&#x20;imidazole&#x20;derivatives&#x20;possessing&#x20;terminal&#x20;sulphonamides&#x20;as&#x20;potential&#x20;BRAF(V600E)&#x20;inhibitors</dcvalue>
<dcvalue element="type" qualifier="none">Article</dcvalue>
<dcvalue element="identifier" qualifier="doi">10.1016&#x2F;j.bioorg.2020.104508</dcvalue>
<dcvalue element="description" qualifier="journalClass">1</dcvalue>
<dcvalue element="identifier" qualifier="bibliographicCitation">BIOORGANIC&#x20;CHEMISTRY,&#x20;v.106</dcvalue>
<dcvalue element="citation" qualifier="title">BIOORGANIC&#x20;CHEMISTRY</dcvalue>
<dcvalue element="citation" qualifier="volume">106</dcvalue>
<dcvalue element="description" qualifier="journalRegisteredClass">scie</dcvalue>
<dcvalue element="description" qualifier="journalRegisteredClass">scopus</dcvalue>
<dcvalue element="identifier" qualifier="wosid">000605009100006</dcvalue>
<dcvalue element="identifier" qualifier="scopusid">2-s2.0-85097429858</dcvalue>
<dcvalue element="relation" qualifier="journalWebOfScienceCategory">Biochemistry&#x20;&amp;&#x20;Molecular&#x20;Biology</dcvalue>
<dcvalue element="relation" qualifier="journalWebOfScienceCategory">Chemistry,&#x20;Organic</dcvalue>
<dcvalue element="relation" qualifier="journalResearchArea">Biochemistry&#x20;&amp;&#x20;Molecular&#x20;Biology</dcvalue>
<dcvalue element="relation" qualifier="journalResearchArea">Chemistry</dcvalue>
<dcvalue element="type" qualifier="docType">Article</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">ANTIPROLIFERATIVE&#x20;ACTIVITY</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">B-RAF(V600E)&#x20;INHIBITORS</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">MULTIKINASE&#x20;INHIBITOR</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">C-RAF</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">B-RAF</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">BRAF</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">KINASE</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">MELANOMA</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">CANCER</dcvalue>
<dcvalue element="subject" qualifier="keywordPlus">DABRAFENIB</dcvalue>
<dcvalue element="subject" qualifier="keywordAuthor">Protein&#x20;kinase&#x20;inhibitors</dcvalue>
<dcvalue element="subject" qualifier="keywordAuthor">BRAF(V600E)&#x20;inhibitors</dcvalue>
<dcvalue element="subject" qualifier="keywordAuthor">Anticancer</dcvalue>
<dcvalue element="subject" qualifier="keywordAuthor">Imidazole</dcvalue>
<dcvalue element="subject" qualifier="keywordAuthor">SAR</dcvalue>
</dublin_core>
